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SYSTEMIC atherosclerosis is closely associated with 
incidence of acute coronary syndrome, cerebrovascular 
ischemia and peripheral arterial diseases.  The vascular 
health should be assessed in patients with cardiovas-
cular risk factors to prevent progression of total vascu-
lar events.  Measurement of maximum carotid intima-
media thickness (IMT) is widely used as a non-invasive 
and reliable surrogate marker for systemic atheroscle-
rosis [1-3], and patients with max IMTs ≥1.1 mm has 
been demonstrated to have an increased risk of cardio-
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Abstract.  Carboxy-terminal telopeptide of type I collagen (ICTP) is generated through matrix metalloproteinase (MMP)-
dependent type I collagen digestion, and has been widely utilized as a biomarker for bone turnover.  The fact that 
atherosclerotic lesions are rich in both type I collagen and MMP-producing macrophages led to the hypothesis that serum 
ICTP concentrations may serve as a non-invasive clinical biomarker for atherosclerosis.  Therefore, the association of 
serum ICTP concentrations with the maximum intima-media thickness (IMT) of carotid arteries, a surrogate index of 
systemic atherosclerosis, or brachial-ankle pulse wave velocity (baPWV) in patients with atherosclerotic risk factors was 
evaluated.  A total of 52 male and 65 female (mean age: 62.8 yrs) patients without renal failure, malignancies or bone 
diseases known to affect serum ICTP concentrations were recruited.  Patients with max IMTs ≥1.1 mm showed significantly 
higher serum ICTP concentrations compared with patients with max IMTs <1.1 mm (3.33 ± 0.97 vs 2.82 ± 0.65 ng/mL, 
p<0.05).  Serum ICTP concentration was also positively correlated with max IMT (p<0.001) or baPWV values (p<0.05).  
Multivariate analyses also revealed that serum ICTP concentrations were correlated with max IMT (p<0.001; 95% CI 
0.200 to 0.454).  These results suggest that serum ICTP concentrations can be used as a non-invasive biomarker for 
systemic atherosclerosis.  
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vascular events compared to those with max IMTs <1.1 
mm [2].  Brachial-ankle pulse wave velocity (baPWV) 
is also utilized as a non-invasive index of systemic ath-
erosclerosis [4, 5].  
Type I collagen is known as a major component of 
collagens localized in the intima, media and adventi-
tia of blood vessel walls [6].  Abnormal metabolism 
of a matrix collagen turnover in a vessel wall even-
tually causes arterial stiffness [7].  In addition, circu-
lating levels of type I collagen-derived peptides such 
as amino-terminal propeptide of procollagen type 
I (PINP) have been proposed as a useful biomarker to 
estimate the levels of cardiovascular fibrosis leading to 
cardiovascular events [8].  Besides PINP, carboxy-ter-
minal telopeptide of type I collagen (ICTP) has also 
been attracting considerable attention, and we previ-
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minescent enzyme immunoassay (Beckman Coulter, 
Bera, USA), respectively.  
The baPWV was measured after resting for 15 min-
utes in the supine position in an air-conditioned room 
using a vascular testing device (Form PWV/ABI, 
Omron Healthcare, Kyoto, Japan).  The four cuffs of 
a volume-plethysmographic device with oscillomet-
ric sensors were wrapped around the upper arms and 
ankles and then inflated automatically and simultane-
ously.  The mean of the right and left baPWV values 
was used for the analysis.  The validity and reproduc-
ibility of the measurements by this device had been 
assessed in previous studies [14, 15].  Ultrasound 
examinations were performed after 15 minutes of rest 
in the supine position using an ultrasound instrument 
with a 12-MHz B-mode transducer (Hitachi EUB-
8500, Hitachi Medical Corporation, Tokyo, Japan). 
The subject’s head and sonographer’s position and the 
scanning angles sequence were standardized.  Bilateral 
common carotid arteries, carotid bifurcation and inter-
nal carotid arteries were scanned.  The greatest intima-
media thickness (IMT) value was recorded as a max 
IMT [16, 17].  All scans were performed by the same 
sonographer, and all image analyses were conducted by 
the same investigators who were blinded to the group 
assignment of the subjects.  
For flow-mediated vasodilation (FMD) measure-
ment, patients were rested for at least 15 minutes in the 
supine position.  Using a 10-MHz linear array transducer 
probe positioned with a hybrid probe holder, longitudi-
nal images of the right brachial artery were recorded at 
baseline, then a forearm-cuff was inflated for five min-
utes at 50 mmHg above the systolic blood pressure just 
prior to FMD measurement [16].  Following cuff defla-
tion, diastolic diameters of brachial arteries were moni-
tored for 2 minutes using an instrument equipped with 
a software program (Unex Co. Ltd., Nagoya, Japan) 
[17].  FMD was then estimated as the percent change 
in the vessel diameter over the baseline value at maxi-
mal dilation during reactive hyperemia.  The intraob-
server variation of %FMD was 4.5%.  
The values are expressed as means ± SD or as a 
percentage for categorical parameters.  Serum ICTP 
levels between groups with and without a carotid plaque 
were compared by an unpaired t-test.  Male gender and 
a presence of hypertension, diabetes mellitus, dyslipid-
emia, or current smoking were coded as dummy vari-
ables.  All the variables were assessed by means of sim-
ple linear regression and stepwise or forced multiple 
ously demonstrated that serum ICTP levels could be a 
non-invasive biomarker for the formation of vulnerable 
plaques in coronary arteries [9].  Because atheroscle-
rotic lesions with vulnerable plaques are rich in type I 
collagen and macrophages producing matrix metallo-
proteinases (MMPs) [10, 11], type I collagen-degraded 
products by MMPs may be abundantly formed in the 
lesions.  Because atherosclerosis progresses concomi-
tantly in a wide variety of arteries [12, 13], ICTP for-
mation may be systematically up-regulated as athero-
sclerosis progresses.  Therefore, the present study was 
undertaken to determine whether serum ICTP levels 
can be used as a surrogate biomarker for the develop-
ment of systemic atherosclerosis.  
Patients and Methods
We recruited patients who visited to Tokushima 
University Hospital due to lifestyle-related diseases 
between March 2008 and April 2013.  After taking a 
written informed consent, we evaluated atherosclerotic 
risk factors, including hypertension, dyslipidemia, dia-
betes mellitus, and current smoking.  Patients with at 
least one of the atherosclerotic risk factors described 
above were enrolled in this study.  We excluded patients 
with overt renal dysfunction, metabolic bone diseases, 
thyroid diseases or known malignancies which may 
affect serum ICTP levels.  Blood samples were taken 
before noon from patients after overnight fasting, and 
serum levels of bone turnover markers including ICTP 
were measured.  Data of work-up study for athero-
sclerosis were collected, including HbA1c, triglycer-
ide (TG), low density lipoprotein cholesterol (LDL-
C), high density lipoprotein cholesterol (HDL-C), 
lipoprotein(a) (Lp(a)) and high sensitivity C-reactive 
protein (hs-CRP).  The levels of TG, LDL-C, HDL-
C, Lp(a), hs-CRP and creatinine (Cr) were measured 
by enzymatic methods.  The estimated glomerular fil-
tration rate (eGFR) was calculated using the following 
latest Japanese equation: eGFR (mL/min/1.73 m2) = 
194 × Age−0.287 × Cr−1.094 (if female, × 0.739).  HbA1c 
levels were assayed using latex agglutination.  Serum 
ICTP levels were measured by a two-antibody telopep-
tide ICTP radioimmunoassay kit (Orion Diagnostica, 
Espoo, Finland).  As bone turnover markers, serum lev-
els of type I collagen cross-linked N-telopeptide (NTX) 
and bone-specific alkaline phosphatase (BSAP) were 
measured by enzyme-linked immunosorbent assays 
(Ostex International, Seattle, USA) and a chemilu-
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mean age 62.8) in this study.  Fifty-three of 65 women 
were postmenopausal state.  The clinical characteristics 
of the patient population are given in Table 1.  Thirty-
six patients were smoking (30.7%); 71 had hyperten-
sion (60.6%); 18 had diabetes mellitus (15.3%); and 71 
had dyslipidemia (60.6%).  All participants had at least 
one of the atherosclerotic risk factors described above; 
16 patients had 3 risk factors; 47 had 2 risk factors; and 
54 had 1 risk factor.  
Correlation of serum ICTP levels with max IMT val-
ues, baPWV and FMD
Serum ICTP levels were measured in all 117 
patients, and found to be distributed between 1.6 and 
7.5 ng/mL (mean 3.21 ± 0.93 ng/mL).  Max IMT was 
ranged from 0.64 to 4.80 mm (mean 1.60 ± 0.83 mm); 
baPWV was from 987 to 2748 cm/sec (mean 1513.1 
± 296.8 cm/sec); and FMD was from 0.2 to 10.3 % 
(mean 4.36 ± 2.11 %) (Table 1).  Eighty-nine patients 
showed max IMT ≥1.1 mm.  The serum levels of ICTP 
were significantly higher in 89 patients with max IMT 
≥1.1 mm than the remaining 28 patients with max IMT 
<1.1 mm (3.33 ± 0.97 vs 2.82 ± 0.65, p<0.05, Fig. 1). 
There were significant positive correlations between 
serum ICTP levels and max IMT (p<0.001, Fig. 2A) 
or baPWV values (p<0.05, Fig. 2B), but not with FMD 
(p=0.367) by simple regression analysis.  
regression analyses.  These analyses were performed 
with SPSS statistics 17.0 for Macintosh (IBM SPSS 
Japan Inc., Tokyo, Japan).  A p value of less than 0.05 
was considered to be statistically significant.  
This study was approved by institutional review 
board of Tokushima University Hospital (No. 2012).  
Results
Patients’ characteristics
We enrolled 52 men and 65 women (41-82 years, 
Table1  Patient characteristics
range
Patient’s number 117
Gender, Male/Female 52/65
post menopausal subject, n/female 53/65
Age (yr) 62.8 ± 11.1 41-82
BMI (kg/m2) 24.6 ± 4.03 19.8-32.2
Current smoking, n (%) 36 (30.8)
Hypertension, n (%) 71 (60.7)
Diabetes mellitus, n (%) 18 (15.4)
Dyslipidemia, n (%) 71 (60.7)
SBP (mmHg) 133.0 ± 19.6 97-185
DBP (mmHg) 77.5 ± 12.8 48-116
PP (mmHg) 55.4 ± 14.8 55-128
TG (mg/dL) 120.4 ± 62.8 30-352
LDL-C (mg/dL) 125.2 ± 30.5 47-194
HDL-C (mg/dL) 60.8 ± 16.4 27-121
Lp(a) (mg/dL) 14.7 ± 10.1 0.2-58.1
Cr (mg/dL) 0.71 ± 0.16 0.42-1.00
eGFR   Total 74.9 ± 17.8 57.0-144.9
Male 74.8 ± 15.1 66.3-113.6
Female 74.5 ± 18.8 57.0-144.9
HbA1c (%) 5.66 ± 0.83 4.4-9.1
hsCRP (mg/dL) 0.20 ± 1.15 0.002-1.14
baPWV (cm/sec) 1513.1 ± 296.8 987-2748
Max-IMT (mm) 1.60 ± 0.83 0.64-4.80
%FMD (%) 4.36 ± 2.11 0.2-10.3
ICTP (ng/mL) 3.21 ± 0.93 1.6-7.5
The values are presented as the mean±SD.  Abbreviation: BMI, 
body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; PP, pulse pressure; TG, triglyceride; LDL-C, low-
density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; Lp(a), lipoprotein a; Cr, creatinine; eGFR, estimated 
glomerular filtration rate; HbA1c, hemoglobin A1c; hsCRP, high-
sensitive c-reactive protein; baPWV, brachial-ankle pulse wave 
velocity; max-IMT, maximum intimamedia thickness; FMD, 
flow-mediated dilatation; ICTP, Carboxy-terminal telopeptide of 
type I collagen
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Fig. 1 Relationship between serum ICTP and max IMT
Serum ICTP level was significantly higher in patients 
with max IMTs ≥1.1 mm compared to the patients with 
max IMTs <1.1 mm (p<0.05).  
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(Table 5).  Serum ICTP levels showed no significant 
relationship with the levels of bone metabolic mark-
ers, BSAP (p=0.134) and NTX (p=0.441).  The values 
of max IMT and baPWV showed no significant rela-
tionship with BSAP (p=0.763, p=0.694, respectively) 
or NTX (p=0.534, p=0.724, respectively), either. 
Collectively, these results demonstrate that serum 
ICTP levels can serve as a surrogate marker for sys-
temic atherosclerosis.  
Discussion
In the present study, serum ICTP levels were dem-
onstrated to be significantly higher in patients with max 
IMT ≥1.1 mm compared to those with max IMT <1.1 
mm.  Significantly positive relationship between serum 
ICTP levels and max IMT or baPWV were observed 
by simple regression analysis.  Furthermore, multi-
variate analysis revealed that serum ICTP levels were 
associated with an increment of max IMT.  Although, 
there were no significant relationship between serum 
ICTP levels and baPWV values in multivariate anal-
ysis (p=0.10), ICTP was still significant determinant 
of baPWV after adjusting SBP.  As an atherosclerotic 
functional index, the decline of FMD could be reflected 
even in early stage of atherosclerosis [18].  In the pres-
Factors correlated with max IMT, baPWV and FMD
Max IMT was positively correlated with age 
(p<0.001), a male gender (p<0.05), hypertension 
(p<0.01), systolic blood pressure (SBP) (p<0.05), 
Lp(a) (p<0.05), Cr (p<0.01), hs-CRP (p<0.05), and 
negatively correlated with HDL-C (p<0.05).  The 
value of baPWV was positively correlated with age 
(p<0.001), hypertension (p<0.001), SBP (p<0.001), 
diastolic blood pressure (DBP) (p<0.05), pulse pres-
sure (PP) (p<0.05) and hs-CRP (p<0.01).  FMD was 
positively correlated with HDL-C (p<0.001), and neg-
atively with hypertension (p<0.01), HbA1c (p<0.05) 
by simple regression analysis (Table2).  Furthermore, 
multivariate analysis revealed that ICTP (p<0.001), age 
(p<0.05), and Lp(a) (p<0.05) were independently and 
positively associated with max IMT (Table 3).  Again, 
ICTP (p<0.05) and age (p<0.001) were still signifi-
cant determinants of max IMT when postmenopausal 
subjects were excluded (Supplementary table 1).  On 
the other hand, multivariate analysis revealed that 
age (p<0.001), SBP (p<0.001), and hsCRP (p<0.01) 
were independently associated with baPWV (Table 4). 
Although the significance of the correlation between 
baPWV and serum ICTP levels disappeared by mul-
tiple regression analysis, we found that the association 
between ICTP and baPWV was independent of SBP 
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Fig. 2 Correlation between serum ICTP and max IMT (A), serum ICTP and baPWV (B) 
Positive correlation was observed between serum ICTP and max IMT at p<0.001 and between serum ICTP and baPWV 
at p<0.05.  
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ent study, FMD was negatively correlated with baPWV 
(r= -0.387, p<0.001) and max IMT (r= -0.238, p<0.01) 
in simple regression analysis.  However, there was no 
correlation between FMD values and serum ICTP lev-
els (p=0.367).  These findings suggested that serum 
ICTP levels were associated with vascular wall remod-
eling rather than endothelial layer remodeling in the 
process of the formation of atherosclerosis.  
Atherosclerotic lesions, particularly with plaques, 
are rich in type I collagen, and macrophages are infil-
trated into these lesions and abundantly produce 
MMPs [10, 19, 20].  Serum levels of MMPs are asso-
ciated with a systemic atherosclerotic burden [21], and 
Table 2  Simple regression analysis for determinants of max IMT, baPWV and FMD
Max IMT baPWV FMD
Coefficient p value Coefficient p value Coefficient p value
Age 0.400 <0.001 0.447 <0.001 - -
Male gender 0.226 <0.05 - - - -
BMI - - - - - -
Current smoking - - - - - -
Hypertension 0.260 <0.01 0.267 <0.01 -0.263 <0.01
DM - - - - - -
Dyslipidemia - - - - - -
SBP 0.193 <0.05 0.422 <0.01 - -
DBP - - 0.224 <0.05 - -
PP - - 0.298 <0.01 - -
HbA1c - - - - -0.194 <0.05
TG - - - - - -
LDL-C - - - - - -
HDL-C -0.205 <0.05 - - 0.323 <0.001
Lp(a) 0.224 <0.05 - - - -
Cr 0.255 <0.01 - - - -
eGFR - - - - - -
hsCRP 0.215 <0.05 0.249 <0.01 - -
ICTP 0.302 <0.001 0.234 <0.05 - -
The abbreviations are the same as those in Table 1.  
Table 3  Multiple regression analysis for determinants of max IMT
β 95% CI T value p value
Age 0.201 0.001 to 0.030 2.001 <0.05
Lp(a)  0.385 0.001 to 0.019 2.329 <0.05
ICTP 0.437 0.200 to 0.454 5.118 <0.001
Variables of the original model included the following: Age, male 
gender, BMI, current smoking, SBP, TG, LDL-C, HDL-C, Lp(a), 
Cr, HbA1c, hsCRP and ICTP.  ICTP (p<0.001), age (p<0.05), and 
Lp(a) (p<0.05) were independently and positively associated with 
max IMT.  The abbreviations are the same as those in Table 1. 
Table 4  Multiple regression analysis for determinants of baPWV
β 95% CI T value p value
Age 0.590 12.002 to 19.361 8.434 <0.001
SBP 0.392 4.244 to 8.177 5.858 <0.001
hsCRP 0.222 16.598 to 94.564 2.828 <0.01
Variables of the original model included the following: Age, male 
gender, BMI, current smoking, SBP, LDL-C, HDL-C, Lp(a), Cr, 
HbA1c, hsCRP and ICTP.  Age (p<0.001), SBP (p<0.001), and 
hsCRP (p<0.01) were positively and independently associated 
with baPWV.  The abbreviations are the same as those in Table 1. 
Table 5  Multiple regression analysis of determinants for 
predictors of baPWV
Model 1 Model 2
β p value β p value
ICTP 0.173 0.067 0.198 <0.05
SBP 0.204 <0.05 0.427 <0.001
Age 0.56 <0.001
Adjusted R2 0.238 0.218
Model 1: ICTP, SBP and age were forced added as parameter for 
determinants of baPWV.  Model 2: ICTP and SBP were forced 
added as parameter for determinants of baPWV.  ICTP was still 
significant determinant of baPWV.  The abbreviations are the same 
as those in Table 1.  
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the expression of MMPs in progressive atherosclerotic 
lesions is markedly elevated [22].  ICTP is a MMP-
dependent degradation product of type I collagen, 
while other type I collagen degradation products such 
as NTX currently used as osteoclastic bone resorption 
markers are formed by cathepsin K-dependent degra-
dation [19].  Metastatic bone lesions of cancers have 
been also known to cause an increase in serum ICTP 
levels through the cancer cell-derived MMP-dependent 
type I collagen degradation in the bone [23].  Because 
there was no significant correlation between the lev-
els of serum ICTP and NTX in the present study, it is 
likely that ICTP is mainly derived from systemic ath-
erosclerotic plaques rather than the age-related osteo-
porotic bone in our cohort.  Our previous study also 
demonstrated that serum levels of ICTP was elevated 
in patients with a history of coronary symptoms and at 
least one coronary plaque with more than 50% stenosis 
[9].  However, mean ICTP concentration in our previ-
ous study was significantly higher than that of the pres-
ent study (7.22 ± 10.10 vs 3.21 ± 0.93, p<0.001).  The 
patients with coronary plaques in our previous study 
appear to have suffered from more advanced and sys-
temic atherosclerosis than the patients of the present 
study.  In fact, all patients enrolled in the present study 
did not experience any chest symptoms with normal 
ECG findings.  This significant difference of serum 
ICTP levels between our previous and the present stud-
ies may depend on total amounts of atherosclerotic 
plaques or severity of systemic atherosclerosis.  
Olsen et al. [24] showed that net synthesis of type I 
collagen was positively correlated with vascular hyper-
trophy and a blood pressure load in patients with essen-
tial hypertension.  Their data suggested that collagen 
synthesis in vascular walls was increased in relation to 
a high hemodynamic load.  Ishikawa et al. [25] showed 
that baPWV was positively correlated with serum lev-
els of procollagen type I C-terminal propeptide (PICP) 
as well as ICTP and also with the ratios of serum lev-
els of tissue inhibitor of matrix metalloproteinase-1 
(TIMP-1) to MMP-1, indices of collagen turnover in 
hypertensive patients.  This study indicated that colla-
gen synthesis and degradation were increased in hyper-
tensive subjects.  MucNulty et al. [26] also reported 
that a type-I collagen synthesis to degradation ratio 
was negatively correlated with baPWV as well as an 
augmentation index, a marker of arterial stiffness, 
whereas serum MMP-1 levels displayed a positive cor-
relation with both baPWV and an augmentation index. 
These studies collectively demonstrated the relation-
ship between collagen metabolism and vascular stiff-
ness or IMT.  
Our study has limitations.  First, this is a cross-sec-
tional study with a relatively small sample size.  Second, 
we were not able to assess if the patients were taking 
medications that would affect IMT and baPWV includ-
ing statins, anti-hypertensives, and so forth.  Third, we 
could not identify subjects with impaired glucose toler-
ance that is known to increase cardiovascular risks [27, 
28].  Further studies on patients with a wider variety of 
conditions will be necessary to define the role of serum 
ICTP levels as a surrogate marker for the development 
of acute coronary syndrome, cerebrovascular accidents 
and peripheral arterial diseases.  
Nonetheless, from the present study, serum ICTP 
levels appeared to be positively correlated with max 
IMT and baPWV values in patients who had at least 
one of atherosclerotic risk factors, and can serve as a 
useful non-invasive biomarker for assessment of sys-
temic atherosclerosis.  
Disclosure
The authors declare no conflicts of interest.  
Supplementary Table 1  Multiple regression analysis of determinants for max 
IMT excluding postmenopausal women
β 95% CI T value p value
Age 0.440 0.015 to 0.048 3.783 <0.001
ICTP 0.255 0.014 to 0.318 2.190 <0.05
Variables of the original model included the following: Age, male gender, BMI, 
current smoking, SBP, DBP, TG, LDL-C, HDL-C, Lp(a), Cr, HbA1c, hsCRP and 
ICTP.  ICTP (p<0.05) and age (p<0.001) were still independently and positively 
associated with max IMT excluding postmenopausal women.  The abbreviations are 
the same as those in Table 1.  
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